Results 61 to 70 of about 52,475 (270)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

open access: yesTH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim   +7 more
doaj   +1 more source

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation

open access: yesPharmaceutics, 2022
Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants (DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data in Thai patients to support precise dosing. This study aimed to develop a
Noppaket Singkham   +7 more
doaj   +1 more source

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]

open access: yes, 2015
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core   +1 more source

Simultaneous Repair of Iatrogenic Left Atrial and Aortic Perforations Using Ductus Arteriosus Occluders: A Case Report

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Iatrogenic perforation of the left atrium and aorta during transseptal puncture (TSP) is a rare but potentially life‐threatening complication. This report presents the case of an elderly male patient with a 20‐year history of atrial fibrillation who experienced this complication during a scheduled left atrial appendage closure procedure ...
Zhihao Wu   +6 more
wiley   +1 more source

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

open access: yesClinical and Applied Thrombosis/Hemostasis
Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH ...
Kaitlin Blotske PharmD   +7 more
doaj   +1 more source

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

open access: yes, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson   +53 more
core   +4 more sources

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik   +7 more
wiley   +1 more source

Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants

open access: yesClinical Medicine Insights: Case Reports, 2015
Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an accidental overdose in a patient with pulmonary thromboembolism, when the patient ...
Dimitar Sajkov, Alexander Gallus
doaj   +1 more source

Home - About - Disclaimer - Privacy